Patrick Burnett sold $158k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 6,287 shares at an average of $25.18, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- +11Trade size$158k at market
- 0Share of holdings soldSold 4.9% of holdings
- +15Cluster7 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.1%, 3m -11.9%, 6m +0.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-014324, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2022 | AGrant or award Common Stock10b5-1 | +16,750 | $0.00 | $0 | 97,401 | Mar 3, 2026 |
| Feb 27, 2026 | AGrant or award Common Stock10b5-1 | +30,000 | $0.00 | $0 | 127,401 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -6,106 | $25.16 | $154k | 121,295 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock10b5-1 | -181 | $25.91 | $4,690 | 121,150 | Mar 3, 2026 |
| Feb 27, 2026 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +77,000 | $0.00 | $0 | 77,000 | Mar 3, 2026 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 23Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 59Moderate | Arcutis Biotherapeutics, Inc. | Terrie Curran director | $956k 38,200 shares | -110% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Terrie Curran director | $28k 1,072 shares | -4% | |
| 36Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $46k 1,697 shares | -1% | |
| 10Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $124k 4,730 shares | -11% | |
| 36Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $395k 15,000 shares | -12% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $114k 4,375 shares | -1% | |
| 15Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $32k 1,230 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.